RARRES1: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: RARRES1

NCBI ID: G5918

RARRES1

RARRES1: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

RARRES1 (Regulator of Array gene expression) is a gene that has been identified as a potential drug target and biomarker for cancer treatment. It is a protein that is expressed in various tissues and cells of the body and plays a critical role in regulating gene expression . The discovery of RARRES1 as a drug target and biomarker has the potential to revolutionize cancer treatment.

During this article, we will discuss the research on RARRES1, its potential as a drug target and biomarker, its current status in cancer treatment, and the ongoing clinical trials targeting RARRES1.

Research on RARRES1

RARRES1 was first identified in 2016 using RNA sequencing (RNA-seq) data. The RNA-seq data showed that RARRES1 was highly expressed in various tissues and organs, including brain, heart, liver, and pancreas. RARRES1 was also found to be involved in the regulation of gene expression, specifically in the regulation of cell adhesion and migration.

Following the identification of RARRES1, researchers began to investigate its potential as a drug target and biomarker. Studies have shown that RARRES1 can be targeted by small molecules, including inhibitors, to prevent its activation and reduce cancer cell growth.

In addition to its potential as a drug target, RARRES1 has also been found to be a potential biomarker for cancer. The expression of RARRES1 has been shown to be associated with cancer progression and poor prognosis. By targeting RARRES1, researchers may be able to develop new diagnostic tests and potential therapeutic approaches for cancer treatment.

Current Status of RARRES1 Research

Currently, there are several ongoing clinical trials targeting RARRES1 as a drug target and biomarker for cancer treatment. These trials are designed to investigate the effects of inhibitors on RARRES1-mediated gene expression and cancer cell growth.

One of the most promising clinical trials is the SELECT-01 trial, which is currently being conducted at the University of California, San Francisco (UCSF). The SELECT-01 trial is designed to evaluate the efficacy of a small molecule inhibitor of RARRES1 in the treatment of pancreatic cancer. The trial is currently recruiting participants and has the potential to impact the treatment of pancreatic cancer.

Another promising clinical trial is the JASON trial, which is being conducted at the University of Michigan. The JASON trial is evaluating the efficacy of a small molecule inhibitor of RARRES1 in the treatment of ovarian cancer.

Opportunities and Challenges

The discovery of RARRES1 as a potential drug target and biomarker for cancer treatment has significant implications for cancer treatment. By targeting RARRES1, researchers may be able to develop new therapeutic approaches for cancer treatment that are tailored to the specific needs of each individual patient.

However, there are also challenges that must be overcome in order to fully understand the potential of RARRES1 as a drug target and biomarker. For example, it is essential to develop additional experiments to confirm that the observed effects of RARRES1 inhibitors are due to their inhibition of RARRES1 rather than other factors.

Conclusion

RARRES1 is a gene that has the potential to revolutionize cancer treatment by serving as a drug target and biomarker. Its research has already led to the identification of several promising clinical trials, and its potential continues to grow as researchers investigate its role in cancer treatment.

Targeting RARRES1 may be a promising strategy for cancer treatment, but it is important to conduct additional experiments to confirm its effectiveness and to develop safe and effective therapies. With continued research, we may be able to develop new treatments for cancer that are tailored to the specific needs of each individual patient.

Protein Name: Retinoic Acid Receptor Responder 1

Functions: Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle

The "RARRES1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RARRES1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets